JPRN-UMIN000011937
Completed
未知
The evaluation of pharmacokinetic and pharmacodynamic properties of Propiverine Hydrochloride transdermal formulation - Pharmacokinetic and pharmacodynamic evaluation of Propiverine Hydrochloride transdermal formulation
Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine0 sites10 target enrollmentOctober 1, 2013
Conditionsoveractive bladder
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- overactive bladder
- Sponsor
- Dept of Clinical Pharmacology and Therapeutics, Oita University Faculty of Medicine
- Enrollment
- 10
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •having skin problems history of allergy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteersEUCTR2010-020197-42-DEInstitut de Recherches Internationales Servier27
Not yet recruiting
Not Applicable
A study on the pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanilNot ApplicableKCT0007066Inje University Busan Paik Hospital15
Completed
Not Applicable
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
Active, not recruiting
Not Applicable
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200